FDA Approves Gedatolisib in Breast Cancer

• by Kathryn Wighton

• July 14, 2026

Deprivation Tied to Lower HNC-Specific QOL

The differences were present before patients began any treatment, suggesting quality-of-life gaps may be established before therapy begins.

• by Andrea Surnit

• June 22, 2026

• 5 min

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.

• by Kathryn Wighton

• July 8, 2026

• 4 min

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

• by Kathryn Wighton

• June 8, 2026

• 3 min